SecBot SecBot
PRESS-RELEASE ·Filed Aug 3, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Quarterly results are not a catalyst, KROS trades on pipeline milestones, not revenue or EPS. The key catalyst to monitor is initial Phase 2 rinvatercept DMD data expected in H1 2027. With $257.6M cash and runway into 2028, the stock is well-capitalized for its current clinical plan. No guidance was provided; the sole financial signal is the cash-burn trajectory.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

KROS drug pipeline →

rinvatercept

● Neutral Named in this press release
Impact
Phase
Phase 2
Time to market
Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.25
T+0 close · Aug 3, 2026 · via day close
Latest settled
+11.46%
T+60 · $11.43
Vs SPY
+11.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $10.25entry
  2. T+1 · 3mo ago −2.49%α −2.29% · $10.00
  3. T+5 · 3mo ago +3.80%α +3.90% · $10.64
  4. T+20 · 3mo ago +8.00%α +9.24% · $11.07
  5. T+60 · 20d ago +11.46%α +11.68% · $11.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics reported Q2 2026 net loss of $28.7M (EPS -$1.45), missing consensus EPS of -$1.24 and zero revenue vs $706K estimate, as prior-year Takeda license revenue did not recur. The pre-revenue clinical-stage biotech initiated its Phase 2 DMD trial for rinvatercept and maintains $257.6M cash with runway into H1 2028. The quarter is routine, the stock will trade on pipeline catalysts, not financials.

Key Financial Metrics

EPS
−$1.45
est −$1.24 · -16.9%
Revenue
$0.00
est $706.0K · -100.0% · -100.0% YoY
Rating
miss

Key Facts

  • Net loss of $28.7M for Q2 2026 vs $30.7M in Q2 2025
  • Zero revenue vs $18.2M in Q2 2025 (prior year included Takeda license revenue)
  • EPS of -$1.45 (consensus -$1.24), 16.9% miss on a tiny pre-revenue base
  • Phase 2 DMD trial for rinvatercept initiated; initial data expected H1 2027
  • Cash and equivalents $257.6M, down from $287.4M at Dec 2025
  • Cash runway into first half of 2028 at current burn rate
  • Weighted-average diluted shares fell to 19.8M from 40.6M a year ago (post-restructuring share count)

Financial Impact

Net loss of $28.7M with operating spend reduction; cash burn ~$30M in Q2 2026 vs $61M in Q2 2025 (prior year included Takeda-related costs). Cash position $257.6M provides ~2-year runway.

revenuenet_losscash_position

Risk Factors

  • Pre-revenue clinical-stage company with no approved products
  • Phase 2 DMD trial results are binary and not expected until H1 2027
  • Cash burn rate will continue; dependency on future financing or partnerships
  • EPS miss mechanically amplified by post-restructuring share count reduction

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3337854

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026